Non-arteritic Anterior Ischemic Optic Neuropathy

Citicoline 1000 mg will be repackaged and given to Group A for 60 days

Group A Citicoline 1000 mg oral tablet

Placebo will be repackaged and given to Group B for 60 days

Group B placebo oral tablet

Departemen Mata Fakultas Kedokteran Universitas Indonesia- RSCM Kirana

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study

amplitude measured from the valley of N35 to the peak of P50 with pattern electroretinography

amplitude measured from peak of P50 to valley of N95 with pattern electroretinography

anatomical cross-sectional examination of retinal ganglion cells using optical coherence tomography (OCT) CirrusTM HD-OCT 5000. The mode is panomap ganglion cell analysis: Macular Cube 512x128 and 200x200 cube Optic disc. Examination is repeated with minimal attention to signal strength is ≥ 5.

visual field test results using Humphrey HFA II-i 750, 24-2 threshold. Examination is repeated by taking into account the confidence index that meets the three criteria below:
Fixation losses ≤ 20%
False positive ≤ 15%
False negative ≤ 20-30%
The parameters assessed are:
The mean deviation (MD): the result of the average sensitivity of the retina of patients compared with the normal population. This figure is obtained from the total deviation.
Pattern standard deviation (PSD): the result of the average sensitivity of the retina of patients who have adapted and showed a localized area index. This figure is obtained from the pattern deviation.

Valen Chia

dr. Valenchia

Sample of 20 people for each treatment group (Group A: citicoline and group B : placebo). Both group were given drug (whether citicoline or placebo) for 60 days.

The allocation of the subject is done by using block randomization. Randomization will be performed by a third party before the study began. Number randomization results will be incorporated into the white envelope sealed and classified into group A (got citcoline) or group B (placebo) in accordance with the results of randomization. Neither the participant, investigator nor the outcome assessor know whether the patient is classified into group A or B.

Diabetic Macular Edema

bevasiranib

Retina Associates of Cleveland

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Diabetic Macular Edema

ribose/edema

Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu